Status:
COMPLETED
A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects
Lead Sponsor:
H. Lundbeck A/S
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the extent to which Lu AF11167 enters the bloodstream following tablet intake and the influence of food on uptake in healthy men and women
Detailed Description
This study will be split into Part A and Part B. Part A will happen first and will look at new tablet formulations of the test medicine compared to a previously known formulation (reference tablet). T...
Eligibility Criteria
Inclusion
- Body mass index (BMI) of ≥18.5 and ≤30.0 kg/m2
- (Part B only) Women of child-bearing potential will have a confirmed non-pregnant and non-lactating status
Exclusion
- The subject has any concurrent disorder that may affect the particular target or absorption, distribution, or elimination of the investigational medical product
- Other in- and exclusion criteria may apply
Key Trial Info
Start Date :
September 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 9 2020
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT04104503
Start Date
September 17 2019
End Date
April 9 2020
Last Update
April 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Quotient
Nottingham, United Kingdom